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Abstract
Introduction
HIV-1 dual infection is a condition that results from infection with at least two HIV-1 variants
from different sources. The scarceness of information on this condition is partly due to the
fact that its detection is technically challenging. Using next-generation sequencing we
defined the extent of HIV-1 dual infection in a cohort of men who have sex with men (MSM).
Material & methods
Eighty-six MSM, diagnosed with HIV-1 subtype B infection between 2008 and 2013 were
selected for next-generation sequencing of the HIV-1 envelope V3. Sequencing was per-
formed on 2 plasma samples collected with an interval of > 6 months before the initiation of
antiretroviral therapy. Maximum likelihood phylogenetic trees were inspected for dual infec-
tion, defined as the presence of two or more monophyletic clusters with 90% bootstrap
support and a mean between-cluster genetic distance of 10%. To confirm dual infection,
deep V3 sequencing of intermediate samples was performed as well as clonal sequencing
of the HIV-1 protease-reverse transcriptase gene.
Results
Five of the 74 patients (6.8%) for whom deep sequencing was successful, showed clear evi-
dence of dual infection. In 4 of them, the second strain was absent in the first sample but
occurred in subsequent samples. This was highly suggestive for superinfection. In 3 patients
both virus variants were of subtype B, in 2 patients at least one of the variants was a subtype
B/non-B recombinant virus.
Conclusions
Dual infection was confirmed in 6.8% of MSM diagnosed with HIV-1 in Belgium. This preva-
lence is probably an underestimation, because stringent criteria were used to classify viral
variants as originating from a new infection event.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) dual infection occurs when an HIV-1 infected
patient is infected by a new viral variant from another host. This results in the presence of two
variants, each originating from an independent infection event. When the second infection
occurs nearly simultaneously with the first, or at least before seroconversion, the condition is
generally called co-infection. When the second infection occurs after seroconversion it is called
superinfection [1]. One of the firmest indications that co- or superinfection is possible is the
existence of recombinant viruses. Recombination between genetically distinct viruses can only
occur after infection of a single cell with both variants. Recombinant viruses can remain
restricted to a single patient (unique recombinant forms; URF) or be further transmitted.
Recombinant forms detected in at least three unrelated individuals are called circulating
recombinant forms (CRF). CRF contribute extensively to the genetic variability of HIV-1 [2,
3] and the constant increase in number of reported CRF (https://www.hiv.lanl.gov/content/
sequence/HIV/CRFs/CRFs.html) suggests high frequencies of dual infection.
The first patient with HIV-1 dual infection was documented in 2002 [4]. Since then, several
other, mostly isolated cases of dual infection, have been reported [1]. Estimates of the overall
frequency of this condition vary between 0 and 20% [5–8]. The number of well documented
superinfections, however, remains low. Difficulties to demonstrate this condition may be the
most important reason for that. Heteroduplex mobility assays [9, 10], multi-region hybridiza-
tion assays [11, 12] and bulk viral sequencing [13, 14] have been used to identify the presence
of different viral variants in the same individual. But all these methods lack sensitivity and
specificity and require additional clonal sequencing as confirmation [9, 14]. With the intro-
duction of next-generation sequencing, enabling the detection of variants representing 1% or
less of a virus population, new possibilities for sensitive detection of dual infection arose [14].
The majority of studies concentrated on intersubtype dual infections [8, 12, 15, 16]. Reports
of dual infection with viruses of the same subtype (intrasubtype dual infection) are much more
limited [17, 18], probably caused by the challenge to differentiate these closely resembling
strains. Alternatively, it is possible that the susceptibility for re-infection is higher when the
second variant is genetically more distinct from the one already present.
An additional difficulty when trying to demonstrate dual infection is that co-presence of
the initial and the superinfecting strain may be limited in time. In an extensive study on the
dynamics of the virus population after superinfection, Chaillon et al. [19] found that only in 2
of the 7 patients both strains co-circulated during the entire follow-up period. In 4 patients the
original strain was rapidly overgrown by the superinfecting strain and in 1 patient a recombi-
nant virus took over [19]. To what extent the level of genetic differences between the initial
and the superinfecting strain influences the population dynamics remains unclear.
Further research on dual infection is needed to elucidate this. Research on co- and superin-
fection may be particularly useful for a better understanding of the host-virus interaction and
provide valuable information for vaccine development.
In Belgium, the overall burden of HIV-1 is limited, but the prevalence in men having sex
with men (MSM) is high, reaching up to 6% in some cities [20]. Because of the high HIV prev-
alence in this specific population, a high risk of dual infection can be assumed. As in other
Western-European countries, the HIV-1 epidemic in MSM is dominated by subtype B [21]. In
this study we therefore specifically focused on the detection of dual infection in HIV-1 subtype
B infected MSM. Eighty-six MSM, diagnosed with HIV-1 infection between 2008 and 2013,
were included. Roche 454 next-generation sequencing of the variable V3 region of the HIV-1
envelope gene was performed to identify dual infection. Clonal sequencing of the HIV-1 prote-
ase-reverse transcriptase region was done to confirm the selected cases of dual infection.
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Materials and methods
Study population
Patients were selected retrospectively from the cohort of HIV-1 infected individuals followed
at Ghent University Hospital. About half of the patients in this cohort are MSM diagnosed
with HIV-1 subtype B infection. We focused specifically on this population and selected 86
patients diagnosed with a subtype B infection between 2008 and 2013 from whom leftover
plasma, collected at two time points with an interval of at least 6 months before initiation of
antiretroviral therapy (ART), was available.
Subtyping
Subtyping of the HIV-1 infection at diagnosis was done using the subtyping tool of Smartgene
IDNS (Smartgene, Zug, Switzerland) and the protease and reverse transcriptase sequences gen-
erated for the purpose of baseline resistance analysis.
Subtyping of the different virus variants present in the patients with dual infection was
done using COMET (Context-based Modeling for Expeditious Typing) HIV-1 (Version 1.0)
[22] and all clonal protease-reverse transcriptase sequences.
Ethical approval
The study was approved by the Ethics Committee of Ghent University Hospital (reference
number 2014/0173). All patients provided informed consent for the use of their leftover
plasma for scientific research. All samples were anonymized before processing.
Viral RNA extraction and preparation of the amplicon library
Viral RNA was extracted from 140 μL of EDTA plasma using the QIAamp Viral RNA Mini kit
(Qiagen, Hilden, Germany). Ten μL of the extracted RNA was reverse transcribed and subse-
quently amplified in one step with the Titan one tube RT-PCR kit (Roche, Basel, Switzerland)
using two sense primers 5’-GAGGATATAATCAGTTTATGG-3’ and 5’-GGATATAATCA
GYYTATGGGA-3’ and two antisense primers 5’-GGTGGGTGCTATTCCTAATGG-3’ and
5’-GGTGGGTGCTAYTCCYAAITG-3’. The resulting amplicon was used as template for the
second, nested amplification with the FastStart High Fidelity PCR SystemTM (Roche, Basel,
Switzerland). The nested primers 5’-TCAACHCAAYTRCTGTTAAATGG-3’ and 5’-ATTT
CTGGRTCYCCKCCTG-3’were extended with Roche multiplex identifiers (MID 1 to MID
34). One unique MID was used per sample. Generated amplicons, containing 345 bp of the V3
region of env (HXB2 position 6,990 to 7,336) were visualized by electrophoresis on a 2% aga-
rose gel. Positive reactions were purified with the Agencourt AMPure XP DNA purification
kitTM (Analis, Ghent, Belgium) and quantified using the Qubit 2.0 fluorometer and Qubit
dsDNA HS Assay kitTM (Life technologies, Carlsbad CA, USA). Thereafter, amplicons were
diluted to a concentration of 109 molecules / μL, pooled and further diluted to a concentration
of 106 molecules/μL.
Next-generation sequencing
Equimolar amplicon mixtures were added to DNA capture beads (Roche, Basel, Switzerland)
at a ratio of 1.4 copies per bead. The resulting solution was used for emulsion PCR executed
with the Lib-A emPCR kit (Roche, Basel, Switzerland). Next-generation sequencing of the
PCR products was performed using the Roche 454 GS Junior next-generation sequencer
according to the manufacturer’s protocol.
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Clonal sequencing of the HIV-1 protease-reverse transcriptase
Viral RNA was extracted from 140 μL of EDTA plasma using the QIAamp Viral RNA Mini kit
(Qiagen, Hilden, Germany) and reverse transcribed using SuperScript™ III reverse transcriptase
(Life Technologies, Carlsbad CA, USA) and the antisense primer 5’-GGGATGTGTACTTCTG
AACTTAYTYTTGG-3’. The resulting cDNA was diluted to a concentration that resulted in a
PCR success rate of maximum 30%. A nested PCR was run with Platinum™ Taq DNA Polymer-
ase High Fidelity (Life Technologies, Carlsbad CA, USA), outer primers 5’-CTCAATAAAG
CTTGCCTTGAGTGC-3’and 5’-GGGATGTGTACTTCTGAACTTAYTYTTGG-3’and inner
primers 5’-AAGTAGTGTGTGCCCGTCTGT-3’ and 5’-CACCTGCCATCTGTTTTCCATA-
3’. Amplicons were purified with Agencourt AMPure beads (Analis, Ghent, Belgium) and sub-
sequently subjected to sequencing of the protease and reverse trancriptase gene using the Big-
Dye™ Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad CA, USA) following
the procedure described before [23]. Sequences were analyzed using the 3500 Genetic Analyzer
(Applied Biosystems, Lennik, Belgium). Proofreading was done using Smartgene IDNS (Smart-
gene, Zug, Switzerland). Sequences with mixed nucleotides were eliminated. Population HIV-1
protease-reverse transcriptase sequences were obtained through routine laboratory activities for
the purpose of drug resistance analysis using an in-house Sanger sequencing protocol.
Data analysis
Sequences generated by next-generation sequencing were trimmed to 228 nucleotides. Identi-
cal reads were clustered before and after manual correction of homopolymer regions using in-
house software and aligned in BioEdit [24]. Reads with a coverage of less than 5 or reads
shorter than 228 nucleotides were removed.
For the sequences generated by clonal or population sequencing, proofreading was done
using Smartgene IDNS (Smartgene, Zug, Switzerland). Concatenated sequences of 831 nucleo-
tides long were then aligned in BioEdit [24].
Phylogenetic analysis
Phylogenetic trees were constructed with PhyML 3.0 using automatic model selection (http://
www.atgc-montpellier.fr/phyml/). The resulting trees were visualized with iTol [25]. Genetic
distances were calculated with MEGA 7 based on the Tamura-Nei model [26]. Highlighter
plots were generated using the highlighter tool created by the Los Alamos sequence database
(https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html).
Recombination analysis was performed with Simplot [27].
Time of infection
Dating of the infection at diagnosis was done using the BED HIV-1 Incidence EIA and the HIV-1
LAg-Avidity EIA (both from Sedia Biosciences Corporation, Portland, Oregon, USA). The analy-
ses were performed on the first sample collected after diagnosis. Only a concordant recent infec-
tion result for both assays was accepted as a valid indication of recent infection, all other results
were interpreted as long-term infections. This approach has been extensively validated for accu-
racy [28] and allows to reliably differentiate infections 130 days from infections> 130 days.
Results
Characteristics of the study population
Next-generation sequencing was attempted on both samples of 86 selected patients. The
sequencing was considered successful if a read coverage of more than 500 was obtained. For
HIV-1 superinfection in MSM
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samples failing this criterion, RNA extraction and next-generation sequencing were repeated.
Sufficient read coverage for both samples was finally obtained for 74 of the 86 patients (86%),
with a median number of sequencing reads per sample of 1588 (IQR: 851–1915). The median
time interval between collection of the two samples analyzed was 25 months (IQR: 15–39).
Forty two patients of the 74 (57%) were classified as recently infected at the time of collection
of the first sample, 32 were diagnosed with a long-term infection. The median age at diagnosis
was 36 years (IQR: 28–46), the median viral load (VL) of the first sample collected was 4.45 log
copies per milliliter (cp/mL) (IQR: 4.05–4.87 log cp/mL) and the median CD4+ T-cell count
was 554 cells/μL (IQR: 422–702 cells/μL).
Identification of dual infection
All next-generation sequences were aligned to construct per patient alignments. These patient
alignments were then randomly combined to assemble 6 large alignments, each including 24
or 25 patients. Each patient was included twice in this exercise but, although shuffling was
done at random, care was taken to avoid that duplicates were included in the same alignment.
A phylogenetic tree was constructed for each of the 6 alignments and visually examined for
clustering. A patient was considered HIV-1 dual infected when his sequences were distributed
over 2 or more clusters with a bootstrap value of 90% in one of the phylogenetic trees. Ten
patients (patients 08, 16, 17, 20, 29, 35, 50, 54, 60 and 66) fulfilled this criterion. For patients
08, 16, 35 and 66, sequences of at least one other patient separated the two phylogenetic clus-
ters, indicating high genetic difference between the variants in these patients. An example phy-
logenetic tree is shown in Fig 1.
The mean genetic distances of the env sequences in the last sample collected from each of
the 74 patients fluctuated between 0.92% and 19.94% (mean 3.28%; IQR 1.78% - 4.02%). For
the 10 patients with a tree topology suggesting dual infection, the mean distances were 19.94%,
13.10%, 11.02%, 8.28%, 4.12%, 6.35%, 4.52%, 4.40%, 4.12% and 2.59% for patients 66, 08, 35,
16, 50, 54, 17, 29, 20 and 60 respectively. As the overall mean genetic distance may be biased in
case of uneven distribution of the variants and is sensitive to differences in the number of se-
quences generated per patient, we also calculated the mean pairwise genetic distance between
the sequences of the two clusters for those patients with a dichotomized tree topology. The
obtained between-cluster mean distances were 56.18%, 30.65%, 26.63%, 24.78%, 12.40%,
9.80%, 8.80%, 8.76%, 8.10% and 7.80% for patients 66, 08, 16, 35, 50, 54, 60, 29, 17 and 20
respectively. Using a cut off of 10%, 5 patients were defined as dually infected. For the 5 other
patients, dual infection was likely but the genetic distance was considered too low for definite
conclusion. Highlighter plots constructed for the 5 patients with confirmed dual infection are
shown in Fig 2. The highlighter plots for the 5 patients with presumed dual infection are pre-
sented in S1 Fig. Further analysis was limited to the patients with confirmed dual infection.
The characteristics of these patients and information on the tested longitudinal samples is
summarized in Table 1.
Analysis of intermediate samples
Intermediate samples from the 5 patients with confirmed dual infection were also subjected to
next-generation V3 sequencing. Three intermediate samples were available for patient 08 and
patient 66 and 2 samples for patient 16 and patient 35. No intermediate samples were available
for patient 50. The per patient phylogenetic trees (Fig 3A–3D) clearly revealed the presence of
2 genetically different viral variants in at least one of the intermediate samples in all 4 patients
(Table 1).
HIV-1 superinfection in MSM
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Fig 1. Example phylogenetic tree visualized with iTol. The tree, rooted on the HXB2 reference, presents the sequences of 25 patients. The sequences of the patients
considered dual infected (patients 35 and 66) are marked with respectively a grey and black circle. Mid-branch filled grey circles indicate a bootstrap value 90%.
https://doi.org/10.1371/journal.pone.0195679.g001
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A significant increase in viral load coinciding with the presumed time point of superinfec-
tion was observed in 2 of the superinfected patients. The viral load increased with 2.19 log cp/
mL in patient 08 and with 0.94 log cp/mL in patient 16 (Table 1).
Analysis of HIV-1 protease-reverse transcriptase sequences
Limiting dilution clonal sequencing of the protease-reverse transcriptase (pol) gene was per-
formed for the viruses isolated from the last sample of the 5 patients with dual infection.
Respectively 11, 14, 21, 11 and 20 clonal sequences were obtained for patients 08, 16, 35, 50
and 66. They were aligned and analyzed together with sequences obtained as part of routine
drug resistance analysis. Sequence alignment, construction of the phylogenetic tree and high-
lighter plots was done as described above for the env sequences. Before phylogenetic analysis,
the alignment was supplemented with a selection of 162 reference sequences from MSM
reflecting the overall sequence variability in the cohort from where the study patients were
selected. Inspection of the resulting phylogenetic tree confirmed the dichotomized topology
Fig 2. Highlighter plots constructed with the env V3 sequences of the 5 patients with dual infection. (A) Patient 08, (B) Patient 16, (C) Patient 66, (D)
Patient 35, (E) Patient 50. Sequences are aligned to the most abundant sequence in the initial sample of each patient. Mutations compared to the first sequence
are color coded.
https://doi.org/10.1371/journal.pone.0195679.g002
Table 1. Characteristics of the 5 patients with HIV-1 dual infection.
Patient
ID
Country of
origin
Infection stage at
diagnosis
Sample
date
Time since first sample
(days)
CD4
count
(cells/μl)
VL
(log c/
mL)
Viral
variants
Subtype
variant 1
Subtype
variant 2
08 Belgium Long-term 6/06/2008 0 1060 4.54 1 B Unassigned
20/02/2009 259 757 4.19 1 (B with
fragments
22/02/2010 626 660 5.13 1 + 2 of A1/D)
24/01/2011 962 627 4.76 1 + 2
19/12/2011 1291 525 5.12 1 + 2
16 Belgium Recent 26/01/2009 0 403 2.71 1 B B
9/06/2009 134 419 2.98 1 + 2
30/10/2009 277 318 5.17 1 + 2
19/01/2010 358 298 4.83 1 + 2
35 Belgium Recent 24/02/2010 0 1020 4.53 1 Majority B B
10/03/2010 14 624 4.58 1 with
fragments
16/06/2010 112 968 4.97 1 + 2 of G
9/01/2013 1050 353 4.32 1 + 2
50 France Long-term 13/01/2011 0 482 3.13 1 + 2 B B
26/03/2012 438 498 3.47 1 + 2
66 Belgium Long-term 19/03/2012 0 555 4.45 1 B B
20/02/2013 338 587 4.69 1 + 2
3/07/2013 471 414 4.28 1 + 2
27/11/2013 618 452 4.83 1 + 2
26/03/2014 737 338 4.76 1 + 2
 Subtyping based on the protease-reverse transcriptase sequence
VL: Viral Load; MSM: Men who have Sex with Men
https://doi.org/10.1371/journal.pone.0195679.t001
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for patients 08, 50 and 66 and revealed a division over at least 3 clusters for patients 16 and 35
(S2 Fig). Highlighter plots (Fig 4) showed patterns highly suggestive for recombination
between the initial and superinfecting strains in patients 16, 66 and 35, an assumption that was
Fig 3. Individual phylogenetic trees of the 4 patients with dual infection from whom more than 2 longitudinal samples were analyzed. (A) Patient 66, (B) Patient
35, (C) Patient 16, (D) Patient 08. Bootstrap values 90% are displayed. Black diamond = HXB2.
https://doi.org/10.1371/journal.pone.0195679.g003
HIV-1 superinfection in MSM
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confirmed by Simplot analysis. The presence of recombinants explains the further branching
of the tree. In patient 16, 50 and 66 all sequences were identified as subtype B. In patient 35
and 08 respectively the initial and the superinfecting strain were identified as a subtype B
recombinant with fragments attributed to subtype G (patient 35) and subtype A and D (patient
08).
Fig 4. Highlighter plots constructed with the pol sequences of the 5 patients with dual infection. (A) Patient 08, (B) Patient 16, (C) Patient 50, (D) Patient 66, (E)
Patient 35. Sequences are aligned to the sequence of the first sample collected from each patient. Mutations compared to this sequence are color coded. P = population
sequencing (numbered by sampling date from old to recent); C = clonal sequencing (numbered by the amount of clones sequenced).
https://doi.org/10.1371/journal.pone.0195679.g004
HIV-1 superinfection in MSM
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Discussion
Phylogenetic analysis of sequences of the V3 region in the HIV-1 envelope gene showed clear
indications for dual infection in 5 (6.8%) of 74 randomly selected MSM diagnosed with HIV-1
in Belgium between 2008 and 2013. This figure is most probably an underestimation, because
stringent criteria were used to consider viral variants as originating from dual infection. For 5
other patients the topology of the phylogenetic tree was suggestive for dual infection but the
genetic difference between the variants was not high enough to confidently exclude that they
evolved from the same founder virus. For 64 (86.5%) of the 74 patients phylogenetic analysis
of V3 sequences could not reveal any indication for dual infection.
The study further concentrated on the 5 patients with high evidence of dual infection. Addi-
tional support for the dual infection was sought by deep sequencing of HIV-1 V3 in intermedi-
ate samples and by clonal analysis of a larger fragment in the protease-reverse transcriptase
gene. In 4 of the 5 patients, a single variant was present in the initial sample with the second
variant detected only in samples collected at a later time point. This is a strong argument for
superinfection. In one patient both variants were already present in the first sample, hamper-
ing discrimination between co- and superinfection. Clonal analysis of the protease-reverse
transcriptase gene of the variants present in the last sample of the 5 patients confirmed the
presence of at least two genetically different variants. Interestingly, in 3 of the 5 patients the
highlighter plots revealed the presence of new recombinant forms containing fragments of
both variants. Based on this information we are confident to state that in the tested MSM pop-
ulation, at least 4 (5.4%) patients are identified with superinfection and 1 (1.4%) with co- or
superinfection. For an additional 5 patients, indications but no convincing evidence for dual
infection were found. These numbers are within the estimated overall frequency of dual infec-
tion reported by others [5–8].
The fact that after diagnosis some MSM continue to have unprotected sex with known sero-
positive partners may be one explanation for the observed high frequency of superinfection.
Some have also suggested that the threshold for superinfection is lower in the early stages of
infection when the immune response has not yet come to full maturation [29–31]. Research
on this is limited but it may be significant that of the 4 superinfected patients identified, 2 were
diagnosed early after infection and superinfection was demonstrated respectively 4 and 5
months after diagnosis. Whether dual or superinfection has implications on the clinical course
of the disease is not clear. In line with the observation of others [18, 32–34], we noticed an
increase in viral load following superinfection in patient 08 and 16. It is therefore important to
consider the possibility of superinfection in case of unexpected rises in viral load.
Extension of the research on dual infection is partly hampered by the lack of a good detec-
tion method. We used next-generation sequencing to screen the genetic variability of the virus
population and defined dual infection based on analysis of the phylogenetic tree, calculation of
the between-cluster mean genetic distance and visual inspection of the highlighter plots. The
outcome of this approach was validated using clonal sequencing of the HIV-1 protease-reverse
transcriptase gene. While establishing the method, the lack of well-defined measures of natu-
rally occurring intrapatient evolution in V3 posed a difficulty. Initially all patients for whom
the V3 sequences were divided over at least two phylogenetic clusters with a bootstrap support
of at least 90% were considered for further analysis. Others have used a less stringent bootstrap
cut-off of 80% [35–37]. In most studies on dual infection the criterion of phylogenetic linkage
is extended with genetic distance calculation and in general a cut-off for pairwise env genetic
distance of 5% is used to discriminate dual infection from intrapatient evolution [18, 34, 37].
The overall mean distance however may be influenced by the distribution of the variants and
will be lower if one variant is much less represented than the other. We therefore opted for the
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use of between-cluster mean distances. These between-cluster distances were high, especially
considering the fact that most were intrasubtype dual infections, but the tree topology and the
highlighter plots indeed confirmed the large differences between the variants.
It is obvious that the chance to detect dual infection increases when the variants are genetically
more distinct. Difficulties to conclude on dual infection with genetically more closely linked vari-
ants may explain why intersubtype dual infection is more frequently reported than intrasubtype
dual infection. Considering the fact that many geographic areas have a predominant subtype [38]
one would expect a higher frequency of intrasubtype recombination. It is possible that the host
immune defense is more successful in preventing re-infection with a highly similar virus than in
preventing re-infections with a virus of a more aberrant genetic background, but there are no data
today to support this hypothesis. Luan et al. detected 18 dual infections in a population of 64 par-
ticipants from the Liaoning province in northeastern China and found equal amounts of intrasub-
type and intersubtype dual infections [37]. Redd et al. examined 149 patients from Uganda and
detected 7 dual infections, 4 intrasubtype and 3 intersubtype [39].
To our knowledge, only one study so far has attempted to analyze the dynamics of the viral
population after dual infection. The results of this study revealed different patterns, with individu-
als in whom both the original and second variant remained detectable over longer periods of
time, individuals in whom one of both variants rapidly overgrew the other variant, and individuals
in whom a recombinant virus took over [19]. This implies that also the timing of the sample col-
lection is important for reliable detection of dual infection, even if highly sensitive techniques are
applied. Our analysis of the protease-reverse transcriptase sequences clearly revealed the presence
of recombinants in 3 of the 5 patients with dual infection. This is remarkable, considering the rela-
tively small genomic fragment analyzed, and deserves further investigation.
A potential hurdle when studying dual infection is the difficulty to discriminate between
co-infection and superinfection. Presence of 2 variants in a single sample can indicate either of
both [40] and only examination of longitudinal samples will allow to discriminate between co-
and superinfection. A limitation of the deep sequencing method that we used for broad scale
screening of dual infection is the short sequence read length. This is a limitation not only of
the Roche 454 technology but of most of the currently available next-generation sequencing
technologies. Ideally, more than one region of the genome must be sequenced to increase the
likeliness of detecting dual infection [41].
In conclusion, using next-generation sequencing, we found a high frequency of dual infec-
tion in our HIV-1 infected MSM population. Methods to easily identify dually infected indi-
viduals will facilitate more in-depth study of this phenomenon and of its consequences for the
patient and the virus. This may provide interesting new insights on the interplay between virus
and host, information that will be of particular interest for future vaccine research.
Supporting information
S1 Fig. Highlighter plots of the 5 patients with potential indications of dual infection. (A)
Patient 54, (B) Patient 60, (C) Patient 29, (D) Patient 20, (E) Patient 17. Sequences are aligned
to the most abundant sequence in the first sample collected. Mutations are color coded.
(PDF)
S2 Fig. Phylogenetic tree containing the pol sequences from the 5 dual infected patients.
This maximum likelihood phylogenetic tree was constructed using pol sequences from 162
MSM and the 5 dual infected patients (08, 16, 35, 50 and 66), rooted on the HXB2 reference.
Visualization with iTol. Mid-branch filled grey circles indicate a bootstrap value 90%.
(PDF)
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